Showing 1 - 4 results of 4 for search 'Arianna Gabrieli', query time: 0.04s Refine Results
  1. 1
    Myb-binding protein 1A (MYBBP1A) is essential for early embryonic development, controls cell cycle and mitosis, and acts as a tumor suppressor.

    Myb-binding protein 1A (MYBBP1A) is essential for early embryonic development, controls cell cycle and mitosis, and acts as a tumor suppressor. by Silvia Mori, Rosa Bernardi, Audrey Laurent, Massimo Resnati, Ambra Crippa, Arianna Gabrieli, Rebecca Keough, Thomas J Gonda, Francesco Blasi

    Published 2012-01-01
    Get full text
    Article
  2. 2
    Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy

    Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy by Laura Milazzo, Laura Pezzati, Letizia Oreni, Cristina Kullmann, Alessia Lai, Arianna Gabrieli, Giovanna Bestetti, Cristian Beschi, Federico Conti, Cosimo Ottomano, Cristina Gervasoni, Luca Meroni, Massimo Galli, Spinello Antinori, Anna Lisa Ridolfo

    Published 2021-12-01
    Get full text
    Article
  3. 3
    Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients

    Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients by Maria Silvia Cona, Agostino Riva, Davide Dalu, Arianna Gabrieli, Cinzia Fasola, Giuseppe Lipari, Giacomo Pozza, Eliana Rulli, Francesca Galli, Lorenzo Ruggieri, Elsa Masedu, Gaia Parma, Davide Chizzoniti, Anna Gambaro, Sabrina Ferrario, Maria Antista, Matteo De Monte, Maciej S. Tarkowski, Nicla La Verde

    Published 2023-06-01
    Get full text
    Article
  4. 4
    Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease

    Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease by Marta Colaneri, Giovanni Scaglione, Federico Fassio, Lucia Galli, Alessia Lai, Annalisa Bergna, Arianna Gabrieli, Maciej Tarkowski, Carla Della Ventura, Valeria Colombo, Laura Cordier, Davide Bernasconi, Mario Corbellino, Gianfranco Dedivitiis, Silvia Borghetti, Debora Visigalli, Salvatore Sollima, Giacomo Casalini, Giuliano Rizzardini, Andrea Gori, Spinello Antinori, Agostino Riva, Monica Schiavini

    Published 2024-03-01
    Get full text
    Article

Search Tools: